2021
Long-Term Quality of Life after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from the Sickle Cell Transplant Evaluation of Long Term and Late Effects Registry (STELLAR)
Arnold S, Bakshi N, Chang Z, Ross D, Abraham A, Bhatia M, Guilcher G, Haight A, Hsieh M, Kasow K, Lane P, Meacham L, Olowoselu F, Krishnamurti L. Long-Term Quality of Life after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from the Sickle Cell Transplant Evaluation of Long Term and Late Effects Registry (STELLAR). Blood 2021, 138: 425. DOI: 10.1182/blood-2021-154280.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseT-scoreSignificant associationTransplant evaluationED visitsHealthcare utilizationPain interferenceCell transplantationCell diseaseRecipients of HCTHLA-identical family donorIdentical family donorLong-term HRQoLFrequency of painEmergency department visitsLong-term survivorsProgressive organ damageChronic persistent painLength of stayAge 18 yearsSAS version 9.4Significant differencesQuality of lifePaucity of data
2015
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children
Brousseau D, Scott J, Badaki-Makun O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Casper T, Cook L, Dean J, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Nimmer M, Panepinto J, Network F. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood 2015, 126: 1651-1657. PMID: 26232172, PMCID: PMC4591790, DOI: 10.1182/blood-2015-05-647107.Peer-Reviewed Original ResearchConceptsSickle cell pain crisisLength of stayPediatric Emergency Care Applied Research NetworkPain crisisIntravenous magnesiumOpioid useNormal saline placeboStudy drug infusionPlacebo-controlled trialHealth-related qualityQuality of lifeMorphine equivalentsStudy drugSaline placeboSecondary outcomesStandard therapyHemoglobin SSPediatric patientsPrimary outcomeDrug infusionPain relieversPlaceboStayChildren 4Group demographics
2014
A Multi-Center Randomized Controlled Trial of Intravenous Magnesium for Sickle Cell Pain Crisis in Children
Brousseau D, Scott J, Badaki O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Casper T, Cook L, Dean M, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Panepinto J. A Multi-Center Randomized Controlled Trial of Intravenous Magnesium for Sickle Cell Pain Crisis in Children. Blood 2014, 124: 88. DOI: 10.1182/blood.v124.21.88.88.Peer-Reviewed Original ResearchSickle cell pain crisisLength of stayAcute chest syndromePediatric Emergency Care Applied Research NetworkQuality of lifePain crisisPediatric emergency medicine physiciansOpioid useIntravenous magnesiumSickle cell diseaseEmergency medicine physiciansMorphine equivalentsPlacebo groupStudy drugAdverse eventsDrug infusionCell diseaseMedicine physiciansHistory of ACSMAGIC studyMulti-Center Randomized Controlled TrialSickle cell vasoocclusive crisisAcute intervention trialDecreased opioid useFirst drug infusion
2010
Lack of Difference In Co-Morbidities Associated with Deep Venous Thrombosis In Patients Undergoing Total Knee Replacement
Viswanathan P, Tiwari U, Krishnamurti L. Lack of Difference In Co-Morbidities Associated with Deep Venous Thrombosis In Patients Undergoing Total Knee Replacement. Blood 2010, 116: 2578. DOI: 10.1182/blood.v116.21.2578.2578.Peer-Reviewed Original ResearchDVT/pulmonary embolismDeep vein thrombosisTotal knee replacementICD-9-CM codesPulmonary embolismDeep venous thrombosisHealth care utilizationNational Inpatient SampleVein thrombosisKnee replacementVenous thrombosisCare utilizationTotal kneeHip replacementPostoperative deep vein thrombosisPostoperative pulmonary embolismGroup of patientsICD-9 codesLength of stayAge 18 yearsPatient safety practicesPost-operative occurrenceKnee replacement recipientsHealth care costsSecondary diagnosis fields